DOCKET NO. 329368-101A

SERIAL NO. 08/854,825

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chisaris, et. al.

Serial No.:

08/854,825

Art Unit:

1648 Parkins 1

Filing Date: Entitled:

May 12, 1997

Examiner:

"Hepatitis C Virus-Derived Peptides Capable of Inducing Cytotoxic T Lymphocyte Responses"

Docket No.

329368-101A

Assistant Commissioner for Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to Examination of this Application, please enter the following amendments:

IN THE CLAIMS:

22. (Twice Amended) (An isolated molecule comprising a polypeptide that induces an hepatitis C virus (HCV)-specific response in cytotoxic T lymphocytes having a sequence that has

> (a) no more than a total of two single amino acid substitutions, deletions or insertions at the corresponding amino acid positions in a CTL epitope which is LLALLSCLTV (Core₁₇₈₋₁₈₇; SEQ ID NO:2), QLRRHIDLLV (E1₂₅₇₋₂₆₆, SEQ ID NO:3), KLVALGINAV (NS31406-1415; SEQ ID NO:28), or LLFNILGGWV (NS4₁₈₀₇₋₁₈₁₆; SEQ ID NO:35), by

> (b) has no more than one single amino acid substitution, deletion or insertion at the corresponding aming acid positions as in a CTL epitope which is ADLMGYIPLV (Core₁₃₁₋₁₄₀; SEQ ID NO:1), DLMGYIPLV (Core₁₃₂₋₁₄₀; SEQ ID NO:54), LLCPAGHAV (NS3116) 1777; SEQ ID NO:26), SLMAFTAAV (NS41789. 1797; SEQ ID NO:34), or ILDSFDPLV (NS52252-2266; SEQ ID NO:42),

wherein said molecule comprises at least eight amino acids and less than 50 amino acids, with the [proviso] provisos that (i) when said selected CTL epitope is SLMAFTAAV (NS4₁₇₈₉₋₁₇₉₇; SEQ ID NO:34), then said molecule comprises from at least eight amino acids to less than 25 amino acids, (ii) when said [polypeptide] selected CTL epitope is LLALLSCLTV (Core₁₇₈₋₁₈₇; SEQ ID NO:2) then said molecule comprises at most ten amino acids, and (iii) when